# Pfizer to Present Over 50 Infectious Disease Pipeline Data Sets at IDWeek 2026

- URL: https://stocks.freetheai.org/news/pfizer-to-present-over-50-infectious-disease-pipeline-data-sets-at-idweek-2026-c9072b
- Published: 2026-10-14T10:45:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NYSE:PFE](https://stocks.freetheai.org/symbols/NYSE-PFE)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Pfizer Inc. (NYSE:PFE) announced that it will present data from more than 50 research abstracts across its infectious disease pipeline at the IDWeek 2026 congress in Washington, D.C., taking place October 21 to October 24, 2026. The presentations include 12 oral sessions highlighting late-stage clinical trials and real-world evidence for both existing products and investigational candidates.

The featured research covers several key developmental milestones, including Phase 2 trial results for a 25-valent pneumococcal conjugate vaccine candidate in infants and Phase 3 data for a Lyme disease vaccine candidate co-developed with Valneva. Additionally, Pfizer will share Phase 3 safety and immunogenicity findings for an LP.8.1-adapted COVID-19 vaccine in high-risk children, alongside real-world effectiveness data for its RSV vaccine, ABRYSVO, and pneumococcal vaccine, PREVNAR 20.

Investors and healthcare professionals will monitor the full presentation readouts during the conference for indications of clinical progress. Key upcoming catalysts include the ongoing Phase 3 pediatric program for the 25-valent pneumococcal candidate and the regulatory review currently underway with the European Medicines Agency for the Lyme disease vaccine candidate.

## Key points

- Pfizer Inc. (NYSE:PFE) will showcase data from over 50 research abstracts across 12 oral presentations at IDWeek 2026 in Washington, D.C.
- Presentation highlights include Phase 2 data for a 25-valent pneumococcal candidate and Phase 3 VALOR study results for a Lyme disease vaccine candidate.
- Additional findings support the safety and immunogenicity of Pfizer's LP.8.1-adapted COVID-19 vaccine in high-risk children aged 5 to 11.
- Real-world evidence will highlight long-term effectiveness for ABRYSVO in nursing homes and PREVNAR 20 in older adults.

## Questions and answers

### What data will Pfizer present at IDWeek 2026?

Pfizer will present findings from over 50 research abstracts across its infectious disease pipeline, including 12 oral presentations on vaccines for pneumococcal disease, Lyme disease, COVID-19, and RSV.

### When and where is IDWeek 2026 being held?

IDWeek 2026 takes place in Washington, D.C., from October 21 to October 24, 2026.

### What is the status of Pfizer's Lyme disease vaccine candidate?

Pfizer is presenting Phase 3 VALOR study results evaluating the efficacy and safety of its Lyme vaccine candidate LB6V, while the European Medicines Agency began reviewing its Marketing Authorization Application in August 2026.